Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19

• Status: Not yet recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.

At this time, there are no specific vaccines or treatments for COVID-19. However, there are many ongoing clinical trials evaluating potential treatments Drugs used to treat malaria infection has shown to be beneficial for many other diseases, including viral infections.

In this Clinical trial, Investigators will evaluate the effect of Artemisinin / Artesunate on morbidity of COVID-19 patients in decreasing the course of the disease and viral load in symptomatic stable positive swab COVID-19 patients. Investigators are hypothesizing that due to the antiviral properties of this drug it will help as a treatment for the COVID -19 patients. In improving their condition and clearing the virus load,

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Princess Nourah Bint Abdulrahman University
• Treatments: Artemisinin; Artemisinine; Artemisinins; Artesunate

Criteria

Inclusion Criteria:

• Adult patient age more than 18 and less than 60 years

• Symptomatic , positive swab covid-19 patients

• Patients who have mild to moderate symptoms

• Patients who have no risk factors like

• Patients who is not on other medications rather those on supportive care

Exclusion Criteria:

• · Patients who have sever disease- shortness of breath, sick patients or admitted in ICU

• Patients who are receiving ventilation supports

• High risk group like :- age more than 60 years, chronic heart diseases, chronic lungs diseases, diabetes, immunocompromised diseases or on immune suppression medications or pregnant women

• Patients who are on other medications which used as treatment for covid 19